CAMBRIDGE, Mass.--(BUSINESS WIRE)--Selventa™ today announced a continuation and expansion of its strategic partnership with the world’s largest pharmaceutical company, Pfizer Inc., in the areas of biological knowledge dissemination and drug safety. The scope of the new collaboration, co-funded by Pfizer, includes creating a publicly available version of Selventa’s Biological Expression Language (BEL) and associated BEL Framework that will enable organizations to capture, store, combine and use scientific knowledge across a wide range of scientific applications to help inform and streamline decision-making regarding drug targets. The collaboration includes establishing a community of BEL stakeholders and users, and the development of a BEL community portal to disseminate the technology to the scientific community at large.
